Source: News Medical Life Sciences, June 2025
Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.
The findings from the UK DANTE phase III trial were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago today (3 June 2025).
The trial, which was funded by a National Institute for Health and Care Research (NIHR) Health Technology Assessment grant, is the largest prospective trial to date to evaluate the best duration to treat inoperable late-stage melanoma with immunotherapy.